Tamsulosin Hydrochloride
Product Images NDC 58118-0598

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Tamsulosin Hydrochloride (NDC 58118-0598). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Clinical Solutions Wholesale, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Tamsulosin 0.4mg

Label for Tamsulosin Hydrochloride 0.4 mg capsules distributed by Clinical Solutions Wholesale, LLC. The label includes the product NDC 58118-0598-8 and a quantity of 30 capsules. Manufacturing details show Aurabindo Pharma Limited as the manufacturer, located in East Windsor, NJ, USA. The label features a barcode, GTIN, batch number, manufacturing lot, and expiration date placeholders.*

FDA Label Image

Figure 1 Mean Plasma Tamsulosin Hydrochloride Concentrations Following Single-dose Administration Of Tamsulosin Hydrochloride Capsules 0.4 mg Under Fasted And Fed Conditions (n=8) (Tamsulosin Fig1)

A line graph depicting mean plasma concentrations of Tamsulosin Hydrochloride over time after a single 0.4 mg capsule dose under fasted and fed conditions in eight subjects. The plasma concentration (ng/mL) is plotted on the Y-axis and time (hours) on the X-axis, showing higher peak concentration and earlier peak time in the fasted state compared to fed.*

FDA Label Image

Figure 2a Mean Change From Baseline In Total Aua Symptom Score (0 To 35) Study 1 (Tamsulosin Fig2)

A line graph showing the mean change from baseline in total AUA Symptom Score over weeks of treatment in a clinical study. The x-axis denotes duration of treatment in weeks, and the y-axis shows mean change. Lines represent three treatment groups: 0.8 mg dose, 0.4 mg dose, and placebo, showing decreasing symptom scores over time, with the 0.8 mg dose group exhibiting the greatest reduction.*

FDA Label Image

Figure 2b Mean Change From Baseline In Total Aua Symptom Score (0 To 35) Study 2 (Tamsulosin Fig3)

A line graph titled 'Figure 2B Mean Change from Baseline in Total AUA Symptom Score (0 to 35) Study 2' showing mean symptom score change over 13 weeks. The x-axis displays treatment duration in weeks with sample sizes, and the y-axis shows mean change from 0 to -11. Three groups are compared: 0.8 mg, 0.4 mg, and placebo. Both 0.8 mg and 0.4 mg groups show greater symptom score reductions than placebo over time.*

FDA Label Image

Figure 3a Mean Increase In Peak Urine Flow Rate (ml/sec) Study 1 (Tamsulosin Fig4)

A line graph titled 'Mean Increase in Peak Urine Flow Rate (mL/Sec) Study 1' showing mean change in mL/sec on the y-axis and duration of treatment in weeks on the x-axis. The graph compares three treatments: 0.8 mg, 0.4 mg, and placebo, illustrating trends in peak urine flow rate increase over a treatment period of up to 13 weeks and last observation carried forward (LOCF).*

FDA Label Image

Figure 3b Mean Increase In Peak Urine Flow Rate (ml/sec) Study 2 (Tamsulosin Fig5)

A line graph titled 'Figure 3B Mean Increase in Peak Urine Flow Rate (mL/Sec) Study 2' showing mean change in urine flow rate (mL/sec) over treatment duration in weeks. The graph compares three treatments: 0.8 mg, 0.4 mg, and Placebo, with data points from week 0 to week 13 and LOCF. The 0.8 mg and 0.4 mg treatments show a higher mean increase than placebo over time.*

FDA Label Image

Chemical Structure (Tamsulosin Str)

Chemical structure of tamsulosin hydrochloride, showing the molecular arrangement including functional groups such as methoxy, sulfonamide, and hydrochloride moiety, consistent with the active ingredient tamsulosin hydrochloride.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.